已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Efficacy and Safety of DP-R202 in Patients with Chronic Artery Occlusive Disease: Multicenter Randomized Double-blind Active-controlled Parallel Group Phase III Clinical Study

医学 双盲 随机对照试验 内科学 外科 病理 安慰剂 替代医学
作者
Han Cheol Lee,Sang Rok Lee,Kyoo Rok Han,Cheol Woong Yu,Chang Gyu Park,Youngkeun Ahn,Han‐Young Jin,Dong Woon Kim,Deok‐Kyu Cho,Seung‐Hyuk Choi,Sang‐Hyun Kim,Ki-yuk Chang,Seung‐Hwan Lee,Wook Bum Pyun,Nam Ho Lee,Woong Chol Kang,Bum‐Kee Hong,Byung Ryul Cho,In‐Ho Chae,Joon‐Han Shin,Kook‐Jin Chun,Doo‐Il Kim,Jae-Won Lee,Young Jae Kim,Donghoon Choi
出处
期刊:Clinical Therapeutics [Elsevier BV]
卷期号:38 (3): 557-573 被引量:2
标识
DOI:10.1016/j.clinthera.2016.01.009
摘要

PurposeSarpogrelate hydrochloride, a selective 5-hydroxytryptamine 2A antagonist, is a widely used antiplatelet agent for the treatment of peripheral arterial disease (PAD). DP-R202 is a new sarpogrelate hydrochloride product with an improved dosage regimen compared with the agent in current use. The aim of this study was to compare the efficacy and safety profile of DP-R202 and Anplag ⁎Trademark: Anplag® Tab (Yuhan Corp, Seoul, Republic of Korea).Trademark: Anplag® Tab (Yuhan Corp, Seoul, Republic of Korea). Tab in patients with PAD.MethodsThis study was a 12-week, multicenter, randomized, double-blinded, active-controlled, parallel group comparative Phase III clinical trial. One hundred fifty-one volunteer patients with PAD were randomized to receive DP-R202 300 mg once daily or Anplag Table 100 mg TID for 12 weeks. The primary end point was a change in patient assessment of lower leg pain intensity with the use of a visual analog scale (VAS) after 12 weeks of treatment. Results after 4, 8, and 12 weeks of treatment were compared with baseline and between treatment groups, and all patients were assessed for adverse events (AEs), clinical laboratory data, and vital signs.FindingsTwo hundred thirty-one patients from 25 medical centers were assessed, and 151 were enrolled and randomly assigned to 1 of 2 treatment groups. Seventy-five patients received DP-R202 300 mg once daily and 76 patients received Anplag Table 100 mg TID for 12 weeks. Analysis of the change in lower leg pain intensity as determined by VAS score between baseline and week 12 (mean [SD], 20.72 [20.06] mm vs 15.55 [21.44] mm) suggested that DP-R202 was not inferior to Anplag Tab, and no significant differences were found in the secondary end points. No significant between-group differences were observed in the prevalence of drug-related clinical- or laboratory-determined AEs. For tolerability, no specific issue was found during the treatment period.ImplicationThe results of this study suggest that DP-R202 was not inferior to Anplag Tab for efficacy in patients with PAD and indicated a good safety profile.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Ava应助何女士采纳,获得10
刚刚
重要问芙brk完成签到,获得积分10
刚刚
钮祜禄萱完成签到 ,获得积分10
5秒前
junkook完成签到 ,获得积分10
6秒前
cao完成签到 ,获得积分10
7秒前
培培完成签到 ,获得积分10
7秒前
甜甜的以筠完成签到 ,获得积分10
8秒前
8秒前
NS完成签到,获得积分10
11秒前
KennyS发布了新的文献求助10
12秒前
落后导师应助李李采纳,获得10
12秒前
12秒前
13秒前
菲比完成签到 ,获得积分10
13秒前
愉快的馒头完成签到,获得积分10
13秒前
15秒前
18秒前
可乐加冰发布了新的文献求助10
20秒前
孤独的小蘑菇完成签到,获得积分10
22秒前
何女士发布了新的文献求助10
22秒前
master-f完成签到 ,获得积分10
29秒前
32秒前
稚祎完成签到 ,获得积分10
35秒前
啦啦啦完成签到 ,获得积分10
38秒前
上官若男应助沐颜采纳,获得10
39秒前
吃的饱饱呀完成签到 ,获得积分10
42秒前
小鸟芋圆露露完成签到 ,获得积分10
43秒前
翟大有完成签到 ,获得积分0
43秒前
朔月完成签到,获得积分10
49秒前
51秒前
失眠的纸鹤完成签到 ,获得积分10
52秒前
Milton_z完成签到 ,获得积分10
54秒前
TangSEU发布了新的文献求助10
57秒前
书文混四方完成签到 ,获得积分10
1分钟前
铮铮完成签到,获得积分10
1分钟前
TangSEU完成签到,获得积分10
1分钟前
辛谷方松永旭完成签到 ,获得积分10
1分钟前
蒋灵馨完成签到 ,获得积分10
1分钟前
坦率的从波完成签到 ,获得积分10
1分钟前
1分钟前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
ISCN 2024 – An International System for Human Cytogenomic Nomenclature (2024) 3000
Continuum Thermodynamics and Material Modelling 2000
Encyclopedia of Geology (2nd Edition) 2000
105th Edition CRC Handbook of Chemistry and Physics 1600
T/CAB 0344-2024 重组人源化胶原蛋白内毒素去除方法 1000
Maneuvering of a Damaged Navy Combatant 650
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3775854
求助须知:如何正确求助?哪些是违规求助? 3321483
关于积分的说明 10205746
捐赠科研通 3036545
什么是DOI,文献DOI怎么找? 1666260
邀请新用户注册赠送积分活动 797334
科研通“疑难数据库(出版商)”最低求助积分说明 757794